News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

TIME has revealed its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives. GRAIL’s Galleri® test was one of the 200 innovations. The Galleri test is a multi-cancer early detection (MCED) test that can detect a shared cancer signal across more than 50 types of cancer through a simple blood draw.

Montana BioScience Alliance
|
November 16, 2022

Central Montana has produced a star in the field of chemistry. Erin Baker, the daughter of Alan and Stephanie Shammel of Hilger and now a Professor of Chemistry at the University of North Carolina, has won several awards for her contributions to the field this year. 

Montana State University
|
September 26, 2022

For a fourth straight year, Montana State University recorded an all-time high for research expenditures, which support scientific discovery, rural outreach and a variety of scholastic pursuits, as well as providing hands-on opportunities for students to engage in science and creative activities that build skills for careers after they earn their degrees

Montana BioSciences Alliance
|
September 18, 2022

In Montana we rally and circle the wagons when a member of our community is suffering, with everyone lending a hand. Our own Senator Jon Tester has demonstrated this truly Montana trait by working to advance policy changes that must occur to alter the course of cancer detection and treatment.

Solo-Dex has announced an exclusive Product Distribution Agreement for Solo-Dex Fascile® suite of products with CH Trading Group LLC, an international import, export and trading company. The Agreement focuses on the MENA regional markets and extends the availability of Solo-Dex Fascile products beyond the U.S., Europe and Brazil to dozens of countries, including those that are part of the Gulf Cooperation Council, the African Union and the Organization of Islamic Cooperation.

ARTICLES OF INTEREST

Bio.News
|
May 22, 2023

Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.

National Institutes of Health
|
May 5, 2023

Information on Small Business Funding Webinar, National Small Business Week, America’s SEED Fund Week — and more

National Institutes of Health
|
March 27, 2023

SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year. The next deadline is April 5. Omnibus Solicitations. Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These FOAs do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations. Specific Funding […]

FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.

Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.

NEWSLETTER

Newsletter
|
April 28, 2023

View the Spring 2023 Newsletter now!

Newsletter
|
February 2, 2023

View the Winter 2022 Newsletter now!